SCHEMBL5545830

SCHEMBL5545830

[O]c1ccccc1-c1nc2ccccc2s1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.64
NPC1 O15118 9/20 0.64
RAB9A P51151 9/20 0.64
ALDH1A1 P00352 7/20 0.64
MAPT P10636 6/20 0.64
SMN1; SMN2 Q16637 5/20 0.64
GAA P10253 5/20 0.64
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
L3MBTL1 Q9Y468 4/20 0.64
TDP1 Q9NUW8 3/20 0.64
NPSR1 Q6W5P4 1/20 0.54
POLB P06746 2/20 0.53
TP53 P04637 2/20 0.51
HSD17B10 Q99714 2/20 0.51
TSHR P16473 1/20 0.51
ILK Q13418 3/20 0.51
GLA P06280 3/20 0.51
HCRTR1 O43613 1/20 0.51
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL231307 0.86 KDM4E (0.75) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL12854008 0.84 KDM4E (0.72) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL28783636 0.80 KDM4E (0.62) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL29602287 0.80 KDM4E (0.62) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL30701858 0.80 KDM4E (0.53) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL827403 0.80 RAB9A (0.67) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL2138149 0.79 KDM4E (0.66) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL196475 0.78 KDM4E (0.73) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL8617042 0.78 KDM4E (0.64) KDM4ENPC1RAB9AALDH1A1MAPT
SCHEMBL22052874 0.78 KDM4E (0.64) KDM4ENPC1RAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11594687-B2 Organic electroluminescent device NOVALED GMBH (DE) 2023-02-28 US claimed
EP-3147962-B1 ORGANIC ELECTROLUMINESCENT DEVICE NOVALED GMBH (DE) 2021-04-21 EP claimed
US-20190058123-A1 Organic Electroluminescent Device NOVALED GMBH (DE) 2019-02-21 US claimed
EP-3182478-B1 ELECTRON INJECTION LAYER FOR AN ORGANIC LIGHT-EMITTING DIODE (OLED) NOVALED GMBH (DE) 2018-11-28 EP claimed
EP-3182478-A1 ELECTRON INJECTION LAYER FOR AN ORGANIC LIGHT-EMITTING DIODE (OLED) Novaled GmbH (DE) 2017-06-21 EP claimed
EP-3147962-A1 ORGANIC ELECTROLUMINESCENT DEVICE Novaled GmbH (DE) 2017-03-29 EP claimed
EP-3147961-A1 ORGANIC ELECTROLUMINESCENT DEVICE Novaled GmbH (DE) 2017-03-29 EP claimed
US-11594687-B2 Organic electroluminescent device NOVALED GMBH (DE) 2023-02-28 US disclosed
EP-3336919-B1 METHOD FOR PREPARING AN ORGANIC ELECTRONIC DEVICE, ORGANIC ELECTRONIC DEVICE, AND A DEVICE COMPRISING THE SAME NOVALED GMBH (DE) 2023-02-22 EP disclosed
US-11145817-B2 Organic light emitting diode comprising an organic semiconductor layer NOVALED GMBH (DE) 2021-10-12 US disclosed
EP-3252837-B1 ORGANIC LIGHT EMITTING DIODE COMPRISING AN ORGANIC SEMICONDUCTOR LAYER NOVALED GMBH (DE) 2021-05-05 EP disclosed
EP-3147962-B1 ORGANIC ELECTROLUMINESCENT DEVICE NOVALED GMBH (DE) 2021-04-21 EP disclosed
EP-3232490-B1 ORGANIC LIGHT EMITTING DIODE COMPRISING AN ORGANIC SEMICONDUCTOR LAYER NOVALED GMBH (DE) 2021-03-17 EP disclosed
EP-3147961-A1 ORGANIC ELECTROLUMINESCENT DEVICE Novaled GmbH (DE) 2017-03-29 EP disclosed
EP-3147962-A1 ORGANIC ELECTROLUMINESCENT DEVICE Novaled GmbH (DE) 2017-03-29 EP disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KDM4E 4854/4885NPC1 2404/4885RAB9A 2824/4885
US-11145817-B2 Organic light emitting diode comprising an organic semiconductor layer C1S, AOC2, SCO2 KDM4E 1905/4885NPC1 1990/4885RAB9A 2440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.